Does Medtech Have an Appetite for M&A?—Boston Scientific
BusinessDoes Medtech Have an Appetite for M&A?—Boston ScientificDoes Medtech Have an Appetite for M&A?—Boston Scientific
Boston Scientific's Commentary on M&A"Near term, our capital allocation priorities are to prepay debt, manage our contingencies and pursue tuck-in M&A."
Sign up for the QMED & MD+DI Daily newsletter.